Curis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading reiterated a Buy rating on the stock and has a $5.00 price target.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Soumit Roy has given his Buy rating due to a combination of factors related to Curis’s upcoming clinical data updates and their strategic focus on key trials. Curis is poised to release significant clinical data at major medical conferences such as SNO, ASH, and ASCO-GI, which could potentially enhance the company’s prospects. The focus on Phase 2 trials in PCNSL and CLL over the next year indicates a strategic direction aimed at advancing their pipeline.
Furthermore, Curis’s recent data from a Phase 1 study involving emavusertib in combination with other treatments showed promising results, including a notable MRD conversion rate in AML patients. The company’s efforts to enroll patients in their Phase 2 study and the anticipated updates from ongoing trials suggest a proactive approach to clinical development. These factors collectively contribute to the positive outlook and Buy rating assigned by Soumit Roy.